Hugel, Inc. (KOSDAQ:145020)

South Korea flag South Korea · Delayed Price · Currency is KRW
317,000
-3,500 (-1.09%)
Aug 28, 2025, 3:30 PM KST
-1.09%
Market Cap3.22T
Revenue (ttm)403.40B
Net Income (ttm)145.72B
Shares Out10.16M
EPS (ttm)12,924.28
PE Ratio24.53
Forward PE22.38
Dividendn/a
Ex-Dividend Daten/a
Volume32,800
Average Volume69,528
Open320,500
Previous Close320,500
Day's Range315,000 - 321,500
52-Week Range229,000 - 392,000
Beta0.40
RSI43.31
Earnings DateAug 7, 2025

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 589
Stock Exchange KOSDAQ
Ticker Symbol 145020
Full Company Profile

Financial Performance

In 2024, Hugel's revenue was 373.05 billion, an increase of 16.69% compared to the previous year's 319.70 billion. Earnings were 135.81 billion, an increase of 45.92%.

Financial Statements

News

Hugel hits record net sales, operating profit in Q3

- Net sales registered KRW105.1 billion and operating profit achieved KRW53.4 billion , up 23.9% and 54.5% on-year, respectively - Net sales of toxin rose 41% on-year, thanks to initial shipment to th...

10 months ago - Benzinga